Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Purine and Pyrimidine Cdk Inhitbitors and Their use for The Treatment of Autoimmune Diseases

a technology of pyrimidine cdk and autoimmune diseases, which is applied in the direction of biocide, plant growth regulators, pharmaceutical non-active ingredients, etc., can solve the problems of abnormal growth of an organ, changes in organ function, and destruction of one or more types of body tissues, and many of the treatments available to date are associated with severe adverse side effects

Inactive Publication Date: 2008-05-29
CYCLACEL
View PDF11 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The patent text describes the use of an inhibitor of CDK2, CDK7, and / or CDK9, or a pharmaceutically acceptable salt thereof, in the treatment of a disease associated with antinuclear antibodies. The inhibitor can be administered alone or in combination with methylprednisolone. The technical effect of this invention is the down-regulation of antinuclear antibodies, which can help to treat the associated disease."

Problems solved by technology

Immune system disorders occur when the immune response is inappropriate, excessive, or lacking.
Autoimmune disorders typically result in destruction of one or more types of body tissues, abnormal growth of an organ, or changes in organ function.
However, autoimmune diseases are often associated with non-specific symptoms such as fatigue, dizziness, malaise (non-specific feeling of not being well), fever, and low-grade temperature elevations.
However, many of treatments available to date are associated with severe adverse side effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Purine and Pyrimidine Cdk Inhitbitors and Their use for The Treatment of Autoimmune Diseases
  • Purine and Pyrimidine Cdk Inhitbitors and Their use for The Treatment of Autoimmune Diseases
  • Purine and Pyrimidine Cdk Inhitbitors and Their use for The Treatment of Autoimmune Diseases

Examples

Experimental program
Comparison scheme
Effect test

examples 1 and 2

Materials and Methods

Proteinuria and Renal Function

[0173]Urinary protein concentration was determined by the Coomassie blue G dye-binding assay with bovine serum albumin as standard. Renal function was assessed as BUN in heparinized blood by the Reflotron test (Roche Diagnostics Corporation, Indianapolis, USA). BUN levels exceeding 30 mg / dl were considered abnormal (normal range in this laboratory for mice: 14-29 mg / dl).

Anti-DNA Antibodies

[0174]The levels of anti-dsDNA autoantibodies were evaluated in the serum by an enzyme-immunoassay (Diastat anti-ds DNA kit, Bouty Laboratory, Milano, Italy) as described before (Kidney Int, 53:726-734, 1998).

Serum Transaminase

[0175]Serum levels of AST and ALT were measured using an autoanalyzer (CX5, Beckman Instruments Inc., Fullerton, Calif.).

Renal Morphology

[0176]Light microscopy: Fragments of renal cortex were fixed in Dubosq-Brazil, dehydrated in alcohol and embedded in paraffin. Sections (3 μm) were stained with hematoxylin and eosin, Masson...

example 1

Results

Body Weight, Food and Water Intake

[0180]As shown in Table 1 lupus mice gained weight during the study. No difference in body weight was observed among the experimental groups. Food (Table 2) and water (Table 3) intake evaluated every two weeks from 2 to 5 months were comparable among vehicle and CYC202 treated mice.

Lupus Mice Survival

[0181]NZB / W F1 mice treated with CYC202 at the doses of 200 and 100 mg / kg, starting from 2 months of age, survived significantly (P<0.05) longer than vehicle-mice (see Table 4 and FIG. 1). Actually, at the end of the study (month 8) while only four of thirteen NZB / W mice (31%) that had been treated with vehicle were alive, ten of thirteen mice (77%) and ten of fourteen mice (71%) treated with 200 and 100 mg / kg CYC202, respectively, survived. In the group of mice given CYC202 (100 mg / kg) from 5 months of age (therapeutic treatment) the percentage of survival was not different from that recorded in vehicle-mice.

Proteinuria and Renal Function

[0182]C...

example 2

Results

Body Weight

[0190]NZB / W F1 mice gained weight during the study. No difference in body weight was observed among the experimental groups.

Survival

[0191]NZB / W F1 mice treated with the combination of CYC202 and methylprednisolone (MPS), starting from 5 months of age, survived significantly (P<0.0001) longer than vehicle-mice (Table 11). Notably, at 12 months, when all mice given vehicle died, ten of sixteen animals (62%) treated with the combined therapy were alive. Survival curves of mice receiving the single therapies were not different from that of vehicle group.

Proteinuria

[0192]Table 12 shows the cumulative percentage of mice with proteinuria >4 mg / day evaluated at different stages of the disease. The association of CYC202 and MPS significantly delayed the onset of proteinuria compared to vehicle. In the interval from 7 to 10 months the proportion of proteinuric mice in the combined therapy group was significantly lower than in the vehicle group (6.2 to 43.8% versus 40 to 90%)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
pHaaaaaaaaaa
volumeaaaaaaaaaa
Login to View More

Abstract

The present invention relates to the use of an inhibitor of CDK2 and / or CDK7 and / or CDK9, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a disease associated with antinuclear antibodies, wherein the inhibitor of CDK2 and / or CDK7 and / or CDK9 or pharmaceutically acceptable salt thereof is administered in an amount sufficient to down-regulate the levels of antinuclear antibodies. A further aspect of the invention relates to a combination comprising an inhibitor of CDK2 and / or CDK7 and / or CDK9, or a pharmaceutically acceptable salt thereof, and methylprednisolone, and its use in the treatment of diseases associated with antinuclear antibodies, such as SLE.

Description

[0001]The present invention relates to a method of treating diseases associated with antinuclear antibodies. More specifically, but not exclusively, the invention relates to methods of treating autoimmune rheumatic diseases such as human systemic lupus erythematosus (SLE), and pharmaceutical compositions and combinations therefor.BACKGROUND TO THE INVENTION[0002]The purpose of the immune system is to protect the body from potentially harmful substances (antigens) such as microorganisms, toxins, cancer cells, and foreign blood or tissues from another person or species. Antigens are destroyed by the immune response, which includes production of antibodies (molecules that attach to the antigen and make it more susceptible to destruction) and sensitized lymphocytes (specialized white blood cells that recognize and destroy particular antigens).[0003]Immune system disorders occur when the immune response is inappropriate, excessive, or lacking. Autoimmune disorders refers to any disease c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/497A61K47/00A61K31/56A61K31/505A61P37/00A61K31/52
CPCA61K31/505A61K31/573A61K31/52A61P13/12A61P19/02A61P19/04A61P29/00A61P37/00A61P37/02A61P37/06A61P43/00
Inventor BENIGNI, ARIELAZOJA, CARLAREMUZZI, GIUSEPPEGIANELLA-BORRADORI, ATHOS
Owner CYCLACEL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com